The phrase "and the reference incidence" is correct and usable in written English.
It can be used in contexts where you are discussing a specific point of reference or occurrence in a study, report, or analysis.
Example: "In our analysis, we will consider the data collected from the previous year and the reference incidence to draw our conclusions."
Alternatives: "and the reference event" or "and the reference occurrence".
Follow-up did not stop at the date of first diagnosis of cancer, and so all primary cancers diagnosed during the follow-up were counted as observed cases and included in the reference incidence rates.
We then calculated the number of iNTS cases for each country by using the reference incidence rates from the cell, according to the assignment of each country in the matrix and each country's population stratified by age groups.
If a matrix cell had >1 data source after the iNTS incidence data were assigned, the mean incidence from all sources was calculated as the reference incidence for that matrix cell.
The capital cities of these northernmost and southernmost states are located at 27.5º south and 42.9º south, respectively (table 1). Figure 1 shows the pattern of risk for multiple sclerosis for each two month period of birth, expressed as an incidence rate ratio for each period of birth relative to the reference incidence rate ratio (1.0) for May-June.
Using atorvastatin, the most widely prescribed statin in Japan, as the reference, incidences of muscle toxicity were statistically indistinguishable among the statins, regardless of the criterion used.
The expected number of cases was calculated using normal population-based age- and sex-specific reference incidence rates from a recently published study on diabetes incidence in the Kronoberg county of southern Sweden (15) and correspondingly stratified patient-years in KIMS.
This study aimed to have at least 300 patients receive the second rituximab infusion at a faster rate so that an increase of at least 3%to4%4% of IRRs from the weighted reference incidence (8% to 9%, based on historical data for rituximab) would be statistically significant.
Australian and UK age-specific cancer incidences were used as the population reference incidences, based on the recent update of the BOADICEA model that incorporates calendar period cancer incidences up to 2010 and country-specific incidences.
Most studies modeled the prescreening incidence trend through the study period to determine reference incidence, though this assumes that incidence would have continued at the same rate without non-linear changes.
Furthermore this study looked only at incident cases, not incidence rates and the reference populations of ReNaM and of the insurance system are not the same.
